MIA PaCa-2

Cat.No.: CSC-C9492L

Species: Homo sapiens (Human)

Source: Pancreas

Morphology: Epithelial-like

Culture Properties: monolayer with floating cells

  • Specification
  • Background
  • Scientific Data
  • Q & A
  • Customer Review
Cat.No.
CSC-C9492L
Description
The MIA PaCa-2 cell line was established from tumor tissue of the pancreas obtained from a 65-year-old Caucasian male in 1975 by A. Yunis, et al. These cells are described to express human colony stimulating factor, subclass I (CSF-I) and plasminogen activator. The established cell line reportedly has a doubling time of about 40 hours and a colony-forming efficiency in soft agar of approximately 19%. Sensitive to L-Asparaginase.

Species
Homo sapiens (Human)
Source
Pancreas
Recommended Medium
Culture Properties
monolayer with floating cells
Morphology
Epithelial-like
STR DNA Profile
Amelogenin: X
CSF1PO: 10
D13S317: 12,13
D16S539: 10,13
D5S818: 12,13
D7S820: 12,13
THO1: 9,10
TPOX: 9
vWA: 15
Karyotype
This is a hypotriploid human cell line. The modal chromosome number is 61. Sixteen to 20 marker chromosomes are commonly found in a cell. A few normal chromosomes are absent.
Application
The MIA PaCa-2 cell line can be used as tumourigenicity and enzymatic studies.
Disease
Pancreatic Ductal Adenocarcinoma
Quality Control
Tests for mycoplasma, bacteria and fungi were negative
Storage and Shipping
Frozen with 52.5% RPMI-1640, 40% FBS, 7.5% DMSO at about 4-5 x 10^6 cells/ampoule; ship in dry ice; store in liquid nitrogen
Synonyms
MIA-PaCa-2; MIA-PACA-2; MIA-Pa-Ca-2; MIA Paca2; MIA PaCa2; MiaPaCa-2; MIAPACA-2; MiaPaca.2; MiaPaCa2; Miapaca2; MIAPaCa2; MIAPACA2; Mia PACA 2; MIAPaCa-2; PaCa2; MiaPaCa
Citation Guidance
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

The MIA PaCa-2 cell line is a foundational and extensively utilized human model of pancreatic ductal adenocarcinoma (PDAC), established in the 1970s from a primary pancreatic tumor in a 65-year-old male patient. It is classified as an epithelial cell line with a notable spindle-shaped, fibroblastoid morphology, indicative of a pronounced epithelial-to-mesenchymal transition (EMT) phenotype, which correlates with its high invasive potential. Genetically, MIA PaCa-2 harbors the cardinal mutations that define PDAC: a homozygous activating mutation in codon 12 of the KRAS oncogene (c.35G>A, p.G12D) and a homozygous inactivating mutation in the TP53 tumor suppressor gene (c.733G>A, p.G245S). This genetic profile drives constitutive proliferative signaling and defective cell cycle control. A distinguishing biochemical feature is its lack of detectable expression of mucins (MUC1, MUC5AC), making it a "null" model for mucin-related studies and differentiating it from other lines like PANC-1 or Capan-2.

The Anti-Cancer Effects of Tilia Species (Linden) Exert on MIA PaCa-2 Cells

This study investigated the anti-cancer effects of the chemically characterized Tilia species (linden) on MIA PaCa-2 cells by analyzing various cancer-triggering mechanisms, including oxidative stress and inflammation status. Extracts from the flowers, bracts, and inflorescences of T. cordata,T. platyphyllos,T. rubra, and T. tomentosa were evaluated for antioxidant activity; subsequently, their ability to mitigate inflammation was assessed through in vitro nitrite assays in LPS-induced RAW264.7 cells. The anticancer potentials of the extracts against MIA PaCa-2 pancreatic cancer cells were investigated in 2D (cytotoxic effect) and 3D (effect on spheroid growth) models in vitro.

All investigated Tilia species displayed remarkable antioxidant activity and significantly inhibited LPS-induced nitrite, IL-6, and PGE2 production. Extract from T. rubra bracts showed the highest cytotoxic activity against MIA PaCa-2 cells with an IC50 value of 0.16 mg/mL, as well as the most significant delay on spheroid growth, which was further confirmed through the arrest in cell cycle. In the Annexin V cell death assays of T. rubra, cells treated with the flower extract exhibited the highest rate of necrotic population with 66.53%.

Overall, the results highlight a potential use for Tilia extracts, particularly T. rubra, in pancreatic cancer treatment by modulating cell death.

Mia PACA-2 three-dimensional spheroid formation/growth after incubation with 1 mg/mL of the different parts of T. rubra extract.

Fig. 1. Images of Mia PACA-2 tumor spheroids after incubation with 1 mg/mL of the different parts of T. rubra extract (Yüksel, Gamze, et al., 2025).

In vitro anti-cancer activity of T. rubra extracts on MIA PaCa-2 cells.

Fig. 2. Effect of T. rubra inflorescence, bract, and flower extracts on the pancreatic carcinoma cell line, MIA PaCa-2, following 24-h treatment (Yüksel, Gamze, et al., 2025).

Ask a Question

Write your own review

  • You May Also Need
CM-1010X

For research use only. Not for any other purpose.

Hot Products